These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 6401828

  • 1. Amyloid proteins, precursors, mediator, and enhancer.
    Cohen AS, Shirahama T, Sipe JD, Skinner M.
    Lab Invest; 1983 Jan; 48(1):1-4. PubMed ID: 6401828
    [No Abstract] [Full Text] [Related]

  • 2. Amyloidosis: a familiar problem in the light of current pathogenetic developments.
    Kisilevsky R.
    Lab Invest; 1983 Oct; 49(4):381-90. PubMed ID: 6353059
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Use of genetically altered mice to study the role of serum amyloid P component in amyloid deposition.
    Maeda S.
    Amyloid; 2003 Aug; 10 Suppl 1():17-20. PubMed ID: 14640037
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Serum amyloid A and protein AA: molecular mechanisms of a transmissible amyloidosis.
    Westermark GT, Westermark P.
    FEBS Lett; 2009 Aug 20; 583(16):2685-90. PubMed ID: 19393650
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A serum AA-like protein as a common constituent of secondary amyloid fibrils.
    Westermark P, Sletten K.
    Clin Exp Immunol; 1982 Sep 20; 49(3):725-31. PubMed ID: 7172504
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Biochemical evidence for the biphasic development of experimental amyloidosis.
    Sipe JD, McAdam KP, Uchino F.
    Lab Invest; 1978 Jan 20; 38(1):110-4. PubMed ID: 621923
    [No Abstract] [Full Text] [Related]

  • 14. Pathogenesis, diagnosis and treatment of systemic amyloidosis.
    Pepys MB.
    Philos Trans R Soc Lond B Biol Sci; 2001 Feb 28; 356(1406):203-10; discussion 210-1. PubMed ID: 11260801
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [AL- and AA-amyloidosis (the status of the problem)].
    Kochubeĭ LN, Vinogradova OM, Serov VV, Vasil'eva NA, Tomas NIu.
    Klin Med (Mosk); 1988 Aug 28; 66(8):7-16. PubMed ID: 3057283
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis.
    Li JP, Galvis ML, Gong F, Zhang X, Zcharia E, Metzger S, Vlodavsky I, Kisilevsky R, Lindahl U.
    Proc Natl Acad Sci U S A; 2005 May 03; 102(18):6473-7. PubMed ID: 15843464
    [Abstract] [Full Text] [Related]

  • 19. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis.
    Arbustini E, Verga L, Concardi M, Palladini G, Obici L, Merlini G.
    Amyloid; 2002 Jun 03; 9(2):108-14. PubMed ID: 12440483
    [Abstract] [Full Text] [Related]

  • 20. Toward understanding the molecular pathogenesis of monoclonal immunoglobulin light-chain deposition.
    Bellotti V, Merlini G.
    Nephrol Dial Transplant; 1996 Sep 03; 11(9):1708-11. PubMed ID: 8918605
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.